Medeva link-ups boost drug shares

Medeva, the pharmaceuticals group, yesterday prompted share price rises across the sector after unveiling collaborations with two biotechnology companies and an upbeat statement on its drugs pipeline.

Peptide Therapeutics saw its shares jump 47.5p to 289p after Medeva said it was spending pounds 3m taking a 2.5 per cent stake in the Cambridge- based group at 340p a share and transferring to it a portfolio of vaccines.

In a separate deal, Medeva is taking on the full clinical development of a "chiral" form of its methylphenidate behaviour modifying drug from Chiroscience, whose shares rose 9p to 327.5p. Medeva's shares ended 8.5p higher at 288p.

The positive news dragged up shares in British Biotech, the UK biotechnology industry's biggest group, by 21.5p to 230p, while Celsis also saw a 2p rise to 112p after announcing a new marketing alliance for its SystemSure hygiene monitoring system with Diversey, part of Unilever.

The Peptide deal will see Medeva hand over certain intellectual property rights to oral and nasal vaccine technology for a consideration of pounds 1m, with a further pounds 1m contingent on development work to be carried out by Medeva over the next two years.

One of the best short-term prospects relates to a vaccine against E coli, the bacteria which has killed 17 people in Scotland in one of the worst outbreaks ever. Clinical trials on that are likely to start next year, while phase one tests on a nasally administered flu vaccine and phase two trials of an oral typhoid vaccine are both due to begin later this year.

Medeva's chief executive, Bill Bogie, said it would retain the right to commercialise the products, giving a royalty to Peptide. The market for vaccines, which was worth pounds 2.1bn in 1995, is expected to double over the next few years.

Meanwhile, analysts welcomed the methylphenidate news as underwriting the future growth prospects for the drug, which in its normal form is Medeva's main product. Chiroscience said a phase one study involving 12 healthy adults had confirmed the tolerability of the new formulation and had demonstrated dosing advantages. Medeva will now take it into commercial development, leading to a regulatory filing expected in the second half of 1999 in both Europe and the US, and will also finance the scaling up of the manufacturing process.

The success of a chiral, or more chemically pure, form of methylphenidate would allow Medeva to patent what is currently just a generic form of Ciba's Ritilin, used in the control of unruly children. Some of the possible benefits of the new drug are that it could be used at half the dose, offer fewer side effects and be more reliably effective across a greater range of people, Mr Bogie said.

Medeva also reported an encouraging response to both the latest phase three trials of its Hepagene compound as a vaccine against hepatitis B and proof of principle tests for its efficacy as a treatment for the disease.

Mr Bogie said Medeva would apply for a licence to sell the vaccine in the US and Europe in 1998 to access a market of 500,000 doses a year. It would decide by mid-year whether to move to commercial development of Hepagene in its treatment form, he added.

Start your day with The Independent, sign up for daily news emails
ebooks
ebooksA special investigation by Andy McSmith
  • Get to the point
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating
and  

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs Money & Business

Ashdown Group: Marketing Manager - B2B, Corporate - City, London

£45000 - £50000 per annum + benefits : Ashdown Group: A highly successful, glo...

Neil Pavier: Commercial Analyst

£50,000 - £55,000: Neil Pavier: Are you a professionally qualified commercial ...

Loren Hughes: Financial Accountant

£45,000 - £55,000: Loren Hughes: Are you looking for a new opportunity that wi...

Sheridan Maine: Finance Analyst

Circa £45,000-£50,000 + benefits: Sheridan Maine: Are you a newly qualified ac...

Day In a Page

General Election 2015: The masterminds behind the scenes

The masterminds behind the election

How do you get your party leader to embrace a message and then stick to it? By employing these people
Machine Gun America: The amusement park where teenagers go to shoot a huge range of automatic weapons

Machine Gun America

The amusement park where teenagers go to shoot a huge range of automatic weapons
The ethics of pet food: Why are we are so selective in how we show animals our love?

The ethics of pet food

Why are we are so selective in how we show animals our love?
11 best bedside tables

11 best bedside tables

It could be the first thing you see in the morning, so make it work for you. We find night stands, tables and cabinets to wake up to
No postcode? No vote

Floating voters

How living on a houseboat meant I didn't officially 'exist'
Louis Theroux's affable Englishman routine begins to wear thin

By Reason of Insanity

Louis Theroux's affable Englishman routine begins to wear thin
Power dressing is back – but no shoulderpads!

Power dressing is back

But banish all thoughts of Eighties shoulderpads
Spanish stone-age cave paintings 'under threat' after being re-opened to the public

Spanish stone-age cave paintings in Altamira 'under threat'

Caves were re-opened to the public
'I was the bookies’ favourite to be first to leave the Cabinet'

Vince Cable interview

'I was the bookies’ favourite to be first to leave the Cabinet'
Election 2015: How many of the Government's coalition agreement promises have been kept?

Promises, promises

But how many coalition agreement pledges have been kept?
The Gaza fisherman who built his own reef - and was shot dead there by an Israeli gunboat

The death of a Gaza fisherman

He built his own reef, and was fatally shot there by an Israeli gunboat
Saudi Arabia's airstrikes in Yemen are fuelling the Gulf's fire

Saudi airstrikes are fuelling the Gulf's fire

Arab intervention in Yemen risks entrenching Sunni-Shia divide and handing a victory to Isis, says Patrick Cockburn
Zayn Malik's departure from One Direction shows the perils of fame in the age of social media

The only direction Zayn could go

We wince at the anguish of One Direction's fans, but Malik's departure shows the perils of fame in the age of social media
Young Magician of the Year 2015: Meet the schoolgirl from Newcastle who has her heart set on being the competition's first female winner

Spells like teen spirit

A 16-year-old from Newcastle has set her heart on being the first female to win Young Magician of the Year. Jonathan Owen meets her
Jonathan Anderson: If fashion is a cycle, this young man knows just how to ride it

If fashion is a cycle, this young man knows just how to ride it

British designer Jonathan Anderson is putting his stamp on venerable house Loewe